Pharmaceutical / Drug Definition :
Inhibits acetylcholine at parasympathetic neuroeffector junction of smooth muscle and cardiac muscle, blocking sinoatrial (SA) and atrioventricular (AV) nodes. These actions increase impulse conduction and raise heart rate. In ophthalmic use, blocks cholinergic stimulation to iris and ciliary bodies, causing pupillary dilation and accommodation paralysis.
In the United States, Atropine Sulfate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Atropine Sulfate.
FDA Label Requirements and Exceptions
FDA Import Information
Atropine Sulfate (Atropine Sulfate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Atropine Sulfate (Atropine Sulfate Suppliers)
- Processors Atropine Sulfate
- Repackers Atropine Sulfate
- Relabelers Atropine Sulfate
- Exporters Atropine Sulfate
- Importers Atropine Sulfate
For more information about Atropine Sulfate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.